SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Trading Update

14 Apr 2026 07:00

RNS Number : 2721A
Oxford Instruments PLC
14 April 2026
Β 

Β 

Oxford Instruments plc

Full-year trading update - 14 April 2026

Β 

Strong second half - full year in line with expectations

Continued strong order momentum in Advanced Technologies

Oxford Instruments plc ("Oxford Instruments" or "the Group"), a leading provider of scientific technology tools, software and expertise to academic and commercial partners, is today issuing a trading update for the year ended 31 March 2026 for continuing operations1.

We expect to deliver a resilient full-year performance in line with market expectations2. Full-year order intake for the Group is expected to be up c. 8% on an organic constant currency (OCC)3Β basis versus prior year, with a book-to-bill ratio of c. 1.07.

After a tariff-disrupted start to the financial year, we have seen continued positive quarter-on-quarter order intake momentum in our Imaging & Analysis ("I&A") division. Following a return to growth in H2, full-year order intake is expected to be in line with the prior year on a reported basis, and marginally up versus prior year on an OCC basis.

Within our Advanced Technologies ("AT") division, tailwinds in the compound semiconductor market, and increasing traction with volume manufacturing customers, have driven c. 30% OCC year-on-year order growth. Order intake accelerated in H2, mainly driven by large US and European commercial customers. Following receipt of a significant multi-year order in April 2026, the current AT order book materially covers planned revenue for FY27, with orders now extending into FY28.

As anticipated, strong execution and improving market conditions in the second half delivered a Group revenue performance significantly ahead of H1, with H2 revenue marginally below the prior year on a reported basis, moving to slightly positive growth on an OCC basis.

Group operating profit margin continued to benefit from the cost restructuring actions undertaken at our Belfast-based imaging business, and from the expected margin improvement from H2 revenue growth.

The first Β£50m tranche of the share buyback programme was completed at the end of February. As at 31 March 2026, Β£11.7m of the second Β£50m tranche had been completed.

Richard Tyson, Chief Executive Officer, commented:

"The Group's strong execution in the second half, coupled with excellent order growth in Advanced Technologies, led to a resilient full-year performance against a challenging external backdrop; testament to the great work and agility of all of the team at Oxford Instruments. With good momentum and a strong order book we are well positioned for growth into the new financial year and beyond."

Β 

FY26 preliminary results

Oxford Instruments management will present its full-year results to analysts and investors at Deutsche Numis, 21 Moorfields, London, EC2Y 9DB on 9 June 2026.

Notes:

1. Excludes the NanoScience business and directly related costs which exited the Group upon final deal closing. All numbers unaudited and based on current expectations.

2. The mean of consensus estimates for reported full year FY26 results are for revenue of Β£420.7m, adjusted operating profit of Β£71.3m, and adjusted operating margin of 16.9%. Please refer to the Company website for more details of how consensus is calculated. Adjusted items exclude the amortisation and impairment of acquired intangible assets, acquisition items, business reorganisation costs, other significant non-recurring items, and the mark-to-market movement of financial derivatives

3. Constant currency numbers are prepared on a month-by-month basis using the translational and transactional exchange rates which prevailed in the previous year rather than the actual exchange rates which prevailed in the year. Transactional exchange rates include the effect of our hedging programme.

Β 

The financial information in this trading update is unaudited. LEI: 213800J364EZD6UCE231

Β 

Enquiries:

Oxford Instruments plc

Richard Tyson, Chief Executive Officer

Paul Fry, Chief Financial Officer

Stephen Lamacraft, Director of Investor Relations 07776 433916

Stephen.lamacraft@oxinst.com

Β 

Β 

MHP Group

Katie Hunt/Tim Rowntree/ 07884 494112

Hugo Harris oxfordinstruments@mhpgroup.com

Β 

Notes to Editors

About Oxford Instruments plc

Oxford Instruments provides academic and commercial organisations worldwide with

market-leading scientific technology and expertise across its key market segments: materials analysis, semiconductors, and healthcare & life science. Innovation is the driving force behind Oxford Instruments' growth and success, supporting its core purpose to accelerate the breakthroughs that create a brighter future for our world. The vigorous search for new ways to make our world greener, healthier and more productive is driving unprecedented levels of R&D investment in new materials and techniques to support productivity and decarbonisation worldwide, creating a significant opportunity for Oxford Instruments to grow. Oxford Instruments holds a unique position to anticipate global drivers and connect academic researchers with commercial applications engineers, acting as a catalyst that powers real world progress. Founded in 1959 as the first technology business to be spun out from Oxford University, Oxford Instruments is now a global, FTSE250 company listed on the London Stock Exchange (OXIG). For more information, visit www.oxinst.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTAKNBNABKDFQD
Date   Source Headline
9th Jul 20132:16 pmPRNHolding(s) in Company
2nd Jul 20132:11 pmPRNBlocklisting - Interim Review
1st Jul 201310:42 amPRNDirector/PDMR Shareholding
26th Jun 20132:57 pmPRNHolding(s) in Company
17th Jun 201310:45 amPRNHolding(s) in Company
12th Jun 20132:53 pmPRNDirector/PDMR Shareholding
11th Jun 20137:00 amRNSFinal Results
11th Jun 20137:00 amRNSAppointment of Non-Executive Director
3rd Jun 20133:44 pmPRNTotal Voting Rights
30th May 201311:34 amPRNDirector/PDMR Shareholding
7th May 201310:08 amPRNTotal Voting Rights
30th Apr 201311:22 amPRNDirector/PDMR Shareholding
29th Apr 20138:53 amPRNHolding(s) in Company
25th Apr 20137:57 amPRNDirector Declaration
23rd Apr 20132:28 pmPRNDirector/PDMR Shareholding
22nd Apr 20131:54 pmPRNAnnual Information Update
19th Apr 201312:01 pmPRNHolding(s) in Company
9th Apr 20137:00 amRNSPre-close Trading Update
2nd Apr 201311:07 amPRNTotal Voting Rights
2nd Apr 201310:26 amPRNDirector/PDMR Shareholding
4th Mar 20132:45 pmPRNTotal Voting Rights
1st Mar 201311:36 amPRNDirector/PDMR Shareholding
13th Feb 20137:00 amRNSInterim Management Statement
13th Feb 20137:00 amRNSCapital Markets Day
7th Feb 20139:33 amPRNHolding(s) in Company
6th Feb 20138:58 amPRNHolding(s) in Company
4th Feb 201311:37 amPRNTotal Voting Rights
4th Feb 20139:26 amPRNHolding(s) in Company
30th Jan 20139:35 amPRNDirector/PDMR Shareholding
8th Jan 201311:46 amPRNHolding(s) in Company
8th Jan 201310:25 amPRNDirectorate Change
3rd Jan 201310:40 amPRNTotal Voting Rights
3rd Jan 201310:33 amPRNBlocklisting - Interim Review
2nd Jan 201312:47 pmPRNDirector/PDMR Shareholding
2nd Jan 201310:20 amPRNHolding(s) in Company
21st Dec 201210:15 amPRNHolding(s) in Company
19th Dec 20121:31 pmPRNHolding(s) in Company
19th Dec 20121:15 pmPRNDirector/PDMR Shareholding
19th Dec 20121:07 pmPRNDirector/PDMR Shareholding
19th Dec 201210:35 amRNSCompletion of Acquisition
17th Dec 20121:46 pmPRNDirector/PDMR Shareholding
17th Dec 20127:00 amRNSAcquisition
3rd Dec 20129:19 amPRNDirector/PDMR Shareholding
20th Nov 201210:56 amPRNHolding(s) in Company
16th Nov 20128:54 amPRNHolding(s) in Company
13th Nov 20127:00 amRNSHalf Yearly Report
30th Oct 201211:56 amPRNDirector/PDMR Shareholding
29th Oct 201211:11 amPRNHolding(s) in Company
23rd Oct 20123:37 pmPRNHolding(s) in Company
22nd Oct 20129:17 amPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.